Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | USP1 | O94782 | 9/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608275 | 0.92 | ADORA2A (0.45) | KDM1AADORA2AADORA1JAK2JAK3 | |
| SCHEMBL12371638 | 0.92 | ADORA2A (0.45) | KDM1AADORA2AADORA1JAK2JAK3 | |
| SCHEMBL13608292 | 0.91 | ADORA2A (0.40) | KDM1AADORA2AADORA1JAK2JAK3 | |
| SCHEMBL12371656 | 0.90 | KDM1A (0.46) | KDM1AADORA2AADORA1JAK2JAK3 | |
| SCHEMBL12371633 | 0.90 | KDM1A (0.46) | KDM1AADORA2AADORA1JAK2JAK3 | |
| SCHEMBL12371640 | 0.90 | KDM1A (0.46) | KDM1AADORA2AADORA1JAK2JAK3 | |
| SCHEMBL13608205 | 0.87 | KDM1A (0.42) | KDM1AJAK2JAK3BRD4ATAD2 | |
| SCHEMBL12371653 | 0.87 | ADORA2A (0.47) | KDM1AADORA2AADORA1JAK2JAK3 | |
| SCHEMBL13608284 | 0.86 | KDM1A (0.43) | KDM1AJAK2JAK3BRD4ATAD2 | |
| SCHEMBL12397531 | 0.86 | KDM1A (0.43) | KDM1AADORA2AADORA1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | KDM1A 1070/4885ADORA2A 975/4885ADORA1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.